

FPI PATIENT ASSISTANCE PROGRAM

The Forest Pharmaceuticals, Inc. (FPI), Patient Assistance Program provides medication for qualifying patients at no charge. If the patient qualifies under FPI guidelines, a three-month supply of the requested drug(s) or device(s) will be shipped to the patient's licensed practitioner for dispensing to the patient. The latest version of this application has a revision date of 1/06. Please discard all unused copies of earlier versions of the application.

Applying for the Program

To apply for the program:

• The patient and licensed practitioner must complete and sign the Patient Assistance Program application form, and the licensed practitioner must attach a prescription (Rx), for a three-month supply, for each drug or device being requested.

Note: If the delivery address on the Rx does not match the delivery or mailing address on the Patient Assistance Program application form, then the licensed practitioner must also attach letterhead or a business card to verify the delivery or mailing address.

Submittal Information

Completed Patient Assistance Program application forms, along with the required prescriptions must be sent to the address at the top of the page.

Note: Copies of a blank Patient Assistance Program application form may be made for future use. However, FPI WILL NOT ACCEPT faxes, emails, or copies of a completed application form.

Application Processing

Please allow 4 weeks for application processing and delivery of medication.

- If the patient is approved, a three-month supply of the drug(s) or device(s) requested will be sent to the licensed practitioner's office for dispensing.
- If the patient is denied, the licensed practitioner and patient will be notified by mail.
- Unless stated otherwise, incomplete applications will be returned to the licensed practitioner or the patient with instructions for completion.
- If you would like notification of the ship date for the requested medication, please write your e-mail address in the space provided.

Applying for Refills

Each time a qualifying patient's prescription needs refilled, a new Patient Assistance Program application form and Rx must be submitted to FPI.

NO FEES APPLY TO THIS PROGRAM.



Dosing and Administration

Recommended maintenance dose is 10 mg BID after titration¹



Titration Schedule¹

Week 1	5 mg once daily
Week 2	10 mg/day (5 mg BID)
Week 3	15 mg/day (10 mg in the morning and 5 mg in the evening)
Week 4 Maintenance Dose	20 mg/day (10 mg BID)

NAMENDA is offered in a convenient Titration Pak, for the first 4 weeks of therapy, to reach the recommended dose¹

Refrence: 1. NAMENDA® (memantine HCI) Prescribing Information. Forest Laboratories, Inc., St. Louis, Mo.

	13645 Shoreline	maceuticals, Inc. • Drive • Earth City MO 63 Namenda® Product Inform	045-1241 • (800) 851 nation: (800) 678-160	-0758 • www.fore 5 or www.namen	stpharm.com/pa da.com	
PART I: PATIER Name:			New App Phone #	olicant: 🗆 Ye :		
Mailing Address	First					
Date of Birth:	Address	P.O Marital Status	. Box City	umber in Hous	ehold:	
What is your gros	ss monthly hous	ehold income? \$	Do you h	ave Medicare Part D	? 🗆 Yes 🗆 No	
		on coverage/reimbursem carrier's name & any ber				
Accountability Act and reg Patient Assistance Program and will be used for purpo practitioner. I further und PAP. I understand that up revoke this authorization a in the PAP and will therea practitioner and the inform information which I agree	gulations thereunder, m ("PAP"). I understa ses of determining m derstand that if my PI pon the furnishing of at any time by providi fifter expire. I certify mation I have provide to provide. I conse	provide Protected Health Inforn "HIPAA") to Forest Pharmaceut and that my PHI will consist of m y eligibility to participate in the HI is incomplete or completed P my PHI to FPI, my PHI may no ng written notice to FPI at the a that I do not have the ability to ed in PART I is correct and I u nt that FPI may contact me for t to FPI's discretion and that FF	icals, Inc. ("FPI") or third pa y name, address, income, pi PAP and to ship appropriate HI does not allow me to par t be subject to all of the pro ddress set forth above. This pay for the medication(s) s nderstand that FPI is entitle verification of my application	rties engaged to assist F escription coverage, and medication(s) as prescrib ticipate in PAP that I may tections and safeguards authorization will extend ubmitted on this applicat d at any time to request n status and receipt of th	PI in administering the F prescription for medicati ped by my licensed medi be notified of such by F provided by HIPAA. I m for as long as I participa on by my licensed medi verification of any of su he indicated medication(
Patient's ORIGINAL signatu	ure		Dat	2		
	2:	TITIONER INFORM	Professional I	Designation:		
Ct License #		DEA #: Phone #:				
Office Contact:			E-mail Addres			
Office Contact: _ Mailing Address:	Address	Suite #	City	St.	Zip	
Office Contact:		Suite # Suite #			Zip Zip	
Office Contact: _ Mailing Address: Delivery Address: If your 1. (Address Medication patient has) Namenda® patient has	Suite # on Information for not already been t Titraton Pak + Name already been titrat	^{City} Namenda®_(mem itrated on Namer enda® 10 mg Tablet ed on Namenda®	st. st. antine HCI) ida® choose op is, #2 (60 ct.) bo choose option	zip tion 1. ttles	
Office Contact: _ Mailing Address: Delivery Address: If your 1. (Address Medication r patient has) Namenda® r patient has 2. (3. (Suite # on Information for not already been t Titraton Pak + Name already been titrat) Namenda [®] 5 mg T) Namenda [®] 10 mg T	^{City} Namenda® (mem itrated on Namer enda® 10 mg Tablet ed on Namenda® Tablets, #3 (60 ct.) Tablets, #3 (60 ct.)	st. st. st. st. st. st. st. st.	zip tion 1. ttles	
Office Contact: Mailing Address: Delivery Address: If your 1. (If your By signing below, I certify reasonable request. I ag provided by me to such e or dispense all or any por	Address Medication patient has) Namenda® patient has 2. (3. (Atta r that the information ree that medication(se eligible participant for rtion thereof for the t of the indicated medicated med	Suite # DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA	City City Namenda® (meministrated on Nameric enda® 10 mg Tabled ed on Namenda® Tablets, #3 (60 ct.) Tablets, #3 (60 ct.) Tablets, #3 (60 ct.) (s) to this applied int o prescriptions provided arge and I will not otherwise her consent that FPI may con-	st. st. st. antine HCI) da® choose op s, #2 (60 ct.) bo choose option bottles) bottles) bottles cation. propriate verification of st by me for an eligible par use any of such medica ntact the patient listed in	Zip tion 1. ttles 2 or 3. uch information upon FP. ticipant in the PAP will I tions or prescribe, provid PART I for verification	
Office Contact: Mailing Address: Delivery Address: If your 1. (If your By signing below, I certify reasonable request. I ag provided by me to such e or dispense all or any por patient status and receipt	Address Medication patient has) Namenda® patient has 2. (3. (Atta that the information ree that medication(s eligible participant for tho the indicated me ate the PAP at any til	Suite # DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA DATA	City City Namenda® (meministrated on Nameric enda® 10 mg Tabled ed on Namenda® Tablets, #3 (60 ct.) Tablets, #3 (60 ct.) Tablets, #3 (60 ct.) (s) to this applied int o prescriptions provided arge and I will not otherwise her consent that FPI may con-	st. st. st. antine HCI) da® choose op s, #2 (60 ct.) bo choose option bottles) bottles) bottles cation. propriate verification of st by me for an eligible par use any of such medica ntact the patient listed in	Zip tion 1. ttles 2 or 3. uch information upon FP. ticipant in the PAP will I tions or prescribe, provid PART I for verification	

Faxed Applications will not be accepted.

FOLD HERE



Place Postage Here

FOREST PHARMACEUTICALS INC SUBSIDIARY OF FOREST LABORATORIES INC PATIENT ASSISTANCE PROGRAM 13645 SHORELINE DR EARTH CITY MO 63045-1241

FOLD HERE

STAPLE OR TAPE CLOSED



FOREST PHARMACEUTICALS, INC. Subsidiary of Forest Laboratories, Inc.

13600 Shoreline Drive • St. Louis, MO 63045 • (314) 493-7000 • Fax (314) 493-7450

Forest Pharmaceuticals Patient Assistance Program & Medicare Part D

Dear Licensed Practitioner and Patient:

Forest Pharmaceuticals, Inc. would like to make you aware of important information regarding our Patient Assistance Program and the new Medicare prescription drug benefit, known as Medicare Part D. Forest Pharmaceuticals Patient Assistant Program (FPI-PAP) has received many phone calls regarding the future of FPI-PAP due to Medicare Part D. Further, current FPI-PAP applicants have asked how their enrollment in Medicare Part D will affect their future participation in FPI-PAP.

Most importantly, FPI-PAP will continue to provide medication assistance to qualifying applicants who have no medical insurance or applicants who have medical insurance without prescription drug benefits. Be assured for these individuals, the FPI-PAP application process will not change. The patient and licensed practitioner will continue to complete and submit an application each time a three-month supply of FPI prescription drug product is needed.

FPI-PAP will not provide FPI prescription drug product to those individuals who have a prescription drug benefit, including Medicare Part D enrollees. Further, Medicare Part D enrollees will not be eligible to participate in FPI-PAP even after the Medicare Part D enrollee has reached their maximum prescription benefit for the calendar year and/or the FPI-PAP prescription drug product is not covered under the Medicare Part D enrollee's prescription drug formulary. New application forms reflecting these rules will be distributed; upon receipt of the new forms all unused copies of current application forms must be discarded.

We strongly encourage Medicare Part D enrollees needing additional assistance to find other sources that will supply medications and/or supplement Medicare Part D prescription coverage. Charitable programs or state funded programs may be of assistance to these individuals.

We at Forest understand the transition from our FPI-PAP to a Medicare Part D prescription coverage plan or other supplemental programs may result in undue hardship to some individuals. Therefore, in such situations, limited assistance through FPI-PAP may be allowed to current FPI-PAP participants on a caseby-case basis during the transition period of calendar year 2006. However, all Medicare Part D enrollees currently participating in our FPI-PAP should prepare to transition to other assistance programs at this time. Continued participation after the patient's current supply of medication is exhausted cannot be assured.

In addition, FPI-PAP representatives cannot answer questions regarding Medicare Part D or other charity or state funded programs. For further information regarding Medicare Part D, please contact the Centers for Medicare & Medicaid Services at 1-800 MEDICARE (1-800-633-4227 or hearing impaired TTY: 1-877-486-2048).

Thank you, Forest Pharmaceuticals, Inc. Patient Assistance Program (800) 851-0758 PAP@forestpharm.com